WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016059502) IN VIVO INDUCED TOXOPLASMA GONDII PROTEIN FOR APPLICATION IN DIAGNOSIS, VACCINE AND THERAPY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2016/059502    International Application No.:    PCT/IB2015/057522
Publication Date: 21.04.2016 International Filing Date: 01.10.2015
IPC:
C07K 14/45 (2006.01), A61K 39/002 (2006.01), C12N 15/30 (2006.01), G01N 33/53 (2006.01)
Applicants: UNIVERSITI SAINS MALAYSIA [MY/MY]; USM Pulau Pinang, 11800 (MY)
Inventors: NOORDIN, Rahmah Binti; (MY).
AMERIZADEH, Atefeh; (MY)
Agent: HEMINGWAY, Christopher Paul; (MY).
JEFFREY, Fiona Teresa; (MY)
Priority Data:
PI2014002940 16.10.2014 MY
Title (EN) IN VIVO INDUCED TOXOPLASMA GONDII PROTEIN FOR APPLICATION IN DIAGNOSIS, VACCINE AND THERAPY
(FR) PROTÉINE DE TOXOPLASMA GONDII INDUITE IN VIVO POUR APPLICATION EN DIAGNOSTIC, VACCIN ET THÉRAPIE
Abstract: front page image
(EN)The present invention relates to methods of screening biological samples for the presence of T. gondii. More particularly, the present invention relates to a sensitive and specific screening test for the presence of Toxoplasmosis in subjects by using or detecting the in vivo-induced T. gondii RAP domain binding protein antigen. The invention further relates to the use of the in vivo-induced antigen in the prevention or therapy of Toxoplasmosis.
(FR)La présente invention concerne des procédés de criblage d'échantillons biologiques pour déterminer la présence de T. gondii. Plus particulièrement, la présente invention concerne un test de criblage sensible et spécifique de la présence de la toxoplasmose chez des sujets grâce à l'utilisation ou à la détection de l'antigène protéique de liaison au domaine RAP de T. gondii induit in vivo. L'invention concerne en outre l'utilisation de l'antigène induit in vivo dans la prévention ou le traitement de la toxoplasmose.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)